159 related articles for article (PubMed ID: 37424811)
1. lncRNA ASBEL and lncRNA Erbb4-IR reduce chemoresistance against gemcitabine and cisplatin in stage IV lung squamous cell carcinoma via the microRNA-21/LZTFL1 axis.
Liang ZY; Zhang ZM; Sun GR; Zhao BS; Xin GH; Zhang L
Am J Cancer Res; 2023; 13(6):2732-2750. PubMed ID: 37424811
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
3. PTPN12 down-regulated by miR-146b-3p gene affects the malignant progression of laryngeal squamous cell carcinoma.
Lan L; Cao H; Zhao L; Cui W; Wang B
Open Med (Wars); 2023; 18(1):20230727. PubMed ID: 37333450
[TBL] [Abstract][Full Text] [Related]
4. LncRNA KCNQ1OT1 contributes to the cisplatin resistance of tongue cancer through the KCNQ1OT1/miR-124-3p/TRIM14 axis.
Qiao CY; Qiao TY; Jin H; Liu LL; Zheng MD; Wang ZL
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):200-212. PubMed ID: 31957833
[TBL] [Abstract][Full Text] [Related]
5. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
Xiao XH; He SY
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
[TBL] [Abstract][Full Text] [Related]
6. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis.
Feng N; Guo Z; Wu X; Tian Y; Li Y; Geng Y; Yu Y
Respir Res; 2021 Sep; 22(1):248. PubMed ID: 34537072
[TBL] [Abstract][Full Text] [Related]
7. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis.
Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X
Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110
[TBL] [Abstract][Full Text] [Related]
8. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis.
Wang L; Shang X; Feng Q
Cancer Biol Ther; 2019; 20(3):261-271. PubMed ID: 30481109
[TBL] [Abstract][Full Text] [Related]
9. Hsa_circ_0007142 contributes to cisplatin resistance in esophageal squamous cell carcinoma via miR-494-3p/LASP1 axis.
Chang N; Ge N; Zhao Y; Yang L; Qin W; Cui Y
J Clin Lab Anal; 2022 May; 36(5):e24304. PubMed ID: 35312115
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of long non-coding RNA B-Raf proto-oncogene-activated non-coding RNA reverses cisplatin resistance in laryngeal squamous cell carcinoma.
Han W; Niu L; Wang L; Liu J; Li H
Arch Med Sci; 2021; 17(5):1164-1174. PubMed ID: 34522245
[TBL] [Abstract][Full Text] [Related]
11. LncRNA NNT-AS1 contributes to the cisplatin resistance of cervical cancer through NNT-AS1/miR-186/HMGB1 axis.
Liu Y; Guo R; Qiao Y; Han L; Liu M
Cancer Cell Int; 2020; 20():190. PubMed ID: 32489326
[TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA ANRIL promotes proliferation, clonogenicity, invasion and migration of laryngeal squamous cell carcinoma by regulating miR-181a/Snai2 axis.
Hao YR; Zhang DJ; Fu ZM; Guo YY; Guan GF
Regen Ther; 2019 Dec; 11():282-289. PubMed ID: 31667207
[TBL] [Abstract][Full Text] [Related]
13. The effects of novel chitosan-targeted gemcitabine nanomedicine mediating cisplatin on epithelial mesenchymal transition, invasion and metastasis of pancreatic cancer cells.
Yu H; Song H; Xiao J; Chen H; Jin X; Lin X; Pan B; Ji W
Biomed Pharmacother; 2017 Dec; 96():650-658. PubMed ID: 29035831
[TBL] [Abstract][Full Text] [Related]
14. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
Cai Y; Dong ZY; Wang JY
Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
[TBL] [Abstract][Full Text] [Related]
15. LncRNA XIST promotes the progression of laryngeal squamous cell carcinoma via sponging miR-125b-5p to modulate TRIB2.
Liu C; Lu Z; Liu H; Zhuang S; Guo P
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32149330
[TBL] [Abstract][Full Text] [Related]
16. LncRNA PCAT6 Accelerates the Progression and Chemoresistance of Cervical Cancer Through Up-Regulating ZEB1 by Sponging miR-543.
Ma Z; Gu G; Pan W; Chen X
Onco Targets Ther; 2020; 13():1159-1170. PubMed ID: 32103984
[TBL] [Abstract][Full Text] [Related]
17. The miR-136-5p/ROCK1 axis suppresses invasion and migration, and enhances cisplatin sensitivity in head and neck cancer cells.
Yang B; Zang J; Yuan W; Jiang X; Zhang F
Exp Ther Med; 2021 Apr; 21(4):317. PubMed ID: 33717260
[TBL] [Abstract][Full Text] [Related]
18. Circ_0030998 Restrains Cisplatin Resistance Through Mediating miR-1323/PDCD4 Axis in Non-small Cell Lung Cancer.
Zhu C; Jiang X; Xiao H; Guan J
Biochem Genet; 2022 Dec; 60(6):2434-2454. PubMed ID: 35460386
[TBL] [Abstract][Full Text] [Related]
19. Circular RNA hsa_circ_0000277 promotes tumor progression and DDP resistance in esophageal squamous cell carcinoma.
Cheng J; Zhang R; Yan M; Li Y
BMC Cancer; 2022 Mar; 22(1):238. PubMed ID: 35241028
[TBL] [Abstract][Full Text] [Related]
20. Identification of circ_0058357 as a regulator in non-small cell lung cancer cells resistant to cisplatin by miR-361-3p/ABCC1 axis.
Chu D; Li P; Li Y; Shi J; Huang S; Jiao P
Thorac Cancer; 2021 Nov; 12(21):2894-2906. PubMed ID: 34523261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
